ASK REDCHAT ANYTHING ABOUT AKARI THERAPEUTICS PLC ADS
Akari Therapeutics plc ADS (NASDAQ: AKTX)
Listen to this Section
$15.35
-0.4950
(
-3.12% )
40.6K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| NomacopanDetailsParoxysmal nocturnal hemoglobinuria |
Phase 3 |
| NomacopanDetailsHematopoietic stem cell transplantation thrombotic microangiopathies |
Phase 3 |
| NomacopanDetailsCOVID-19 |
Phase 2 |
| NomacopanDetailsAtopic Keratoconjunctivitis |
Phase 1/2 |
| NomacopanDetailsGeographic atrophy, Eye disease |
Phase 1 |
| NomacopanDetailsBullous pemphigoid |
Failed |
Market Data
|
| Open |
$15.35 |
| Previous Close |
$15.84 |
| Volume |
40.6K |
| Market Cap |
$17.15M |
| Day Range |
$14.71 - $16.71 |
| 52 Week Range |
$3.02 - $54.00 |
| Shares Outstanding |
1.14M |
| Change % |
-3.12% |
| Net Change |
▼ -0.4950 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2012 |
| Country | United Kingdom |
Insider Ownership Transactions
Total Amount Purchased:
-3,404,356,151.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-04-30 |
Sale |
-479569892.00 |
Jacques Rachelle Suzanne |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-k |
Annual reports |
95 |
Mar 30, 2026 |
| 8-k |
8K-related |
14 |
Mar 17, 2026 |
| 4 |
Insider transactions |
2 |
Mar 16, 2026 |
| schedule |
Other |
1 |
Mar 04, 2026 |
| schedule |
Other |
1 |
Mar 04, 2026 |
| schedule |
Other |
1 |
Mar 04, 2026 |
| 8-k |
8K-related |
14 |
Mar 02, 2026 |
| def |
Proxies and info statements |
5 |
Feb 02, 2026 |
| s-1 |
Registration statements |
129 |
Jan 23, 2026 |
| pre |
Proxies and info statements |
5 |
Jan 22, 2026 |